MannKind (NASDAQ:MNKD) Lowered to Sell at Zacks Investment Research

MannKind (NASDAQ:MNKD – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as […]

Related Keywords

United States ,Anthonyc Hooper ,Alejandro Galindo ,Russell Investments Group Ltd ,Zacks Investment Research ,Mannkind Company Profile Get Rating ,Mannkind Corporation ,Company Medtone ,Waltman Capital ,Oakworth Capital Inc ,Macquarie Group Ltd ,Paradigm Financial Partners ,Get Rating ,Technosphere Insulin System ,Director Anthony ,Investments Group ,Kind Company Profile ,Kind Corporation ,Mannkind ,Nasdaq Mnkd ,Mnkd ,Medical ,56400p20 ,Downgrade ,